Le Lézard
Classified in: Health
Subject: RCL

Food Recall Warning - Louis Latour brand Pinot Noir recalled due to possible presence of glass


Product photo is available:  https://recalls-rappels.canada.ca/en/alert-recall/louis-latour-brand-pinot-noir-recalled-due-possible-presence-glass

OTTAWA, ON, Feb. 18, 2023 /CNW/ -

Summary
Affected products

Brand

Product                       

Size

UPC                      

Codes        

Louis Latour   

Pinot Noir Bourgogne
2021

375 mL   

3 566922 002975

L2217977
L2221076
L2221065
L2221077

 

Issue

The affected product is being recalled from the marketplace due to the possible presence of glass.

The recalled product has been sold in Ontario.

What you should do

Learn more:

Background

This recall was triggered by a recall in another country.

There have been no reported injuries associated with the consumption of this product.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products.

The CFIA is verifying that industry is removing recalled products from the marketplace.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: